Online Education

22HT00046 – Understanding Hemophilia

February 24, 2022

5:00 PM Eastern, February 23, 2024
The estimated time to complete this activity is 120 minutes.

"Understanding Hemophilia" is a 6-part online learning activity that aims to enable clinicians at U.S. Hemophilia Treatment Centers to gain knowledge and develop expertise on the pathogenesis, inheritance, symptoms, potential complications, and clinical management of hemophilia.

This 6-part online learning activity introduces basic concepts of hemophilia.

Part 1: Pathogenesis & Inheritance examines the coagulation system and processes, the deficit in hemophilia that interferes with clot formation, differences among types of hemophilia, and the sex-linked inheritance pattern of hemophilia.

Part 2: Symptoms & Sequelae distinguishes bleeding patterns and clinical presentation of hemophilia based on severity, differentiates types of bleeding episodes, and discusses physical/psychosocial sequelae of hemophilia.

Part 3: Factor Concentrates & Hemophilia Management discusses episodic and prophylactic management of hemophilia with clotting factor concentrate, different factor therapy protocols, and nursing considerations in administration of clotting factor concentrates.

Part 4: Introduction to Inhibitors explains the immune response and inhibitor development, signs/symptoms and risk factors of inhibitors, the impact of inhibitors on persons with hemophilia, inhibitor treatment strategies and challenges, and the positive health outcomes of immune tolerance induction therapy.

Part 5: Emicizumab covers the novel agent emicizumab, including its indications, mechanism of action, dosing options, lab considerations; as well as management of breakthrough bleeding, the boxed warning of emicizumab, use of emicizumab concurrently with bypassing agents, and potential considerations in the management of persons with hemophilia with or without inhibitors who utilize emicizumab.

Part 6: Carrier Considerations reviews hemophilia sex-linked genetics and introduces recommendations for the management of carriers and women with hemophilia, neonatal diagnosis and circumcision in males with hemophilia, and key considerations of postpartum management of carriers and women with hemophilia.

This enduring material is intended for nurses, nurse practitioners, physician assistants, and other clinical staff within the federally recognized U.S. Hemophilia Treatment Center (HTC) network who wish to develop an understanding of basic concepts of hemophilia. The activity is particularly appropriate for clinicians within their first six months of employment at an HTC.

• Describe the pathogenesis and inheritance patterns concerning the different factor deficiencies in hemophilia including the symptoms and sequelae that may occur
• Discuss the target factor levels for situational bleeding episodes in conjunction with the appropriate factor replacement protocols, prophylactic treatments, and nursing considerations in administration of clotting factor concentrates
• Review the development and impact of inhibitors on persons with hemophilia, including signs and symptoms, risk factors, treatment implications, and nursing considerations
• Summarize the MASAC recommendations on the use of Emicizumab such as the indications, management approaches, and concurrent use with bypassing agents
• Articulate the role of genetic testing in the identification of potential carriers and women with hemophilia and the hemostatic management recommendations during pregnancy, labor and delivery, and the postpartum phases

• Jennifer Maahs, MSN, PNP, RN-BC
• Amy Shapiro, MD

In order to receive continuing education credits, you must complete these steps prior to the activity expiration date

• Read the Disclosure Information found in the To Dos section.
• Complete the learning activity
• Complete the evaluation
• Complete the post-test with a score of 80% or better.
• Upon successful completion of the post-test your certificate of completion will be available to print or save

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Partners in Bleeding Disorders Education Program. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NURSES/NURSE PRACTITIONERS

The University of Nebraska Medical Center designates this activity for 2.0 ANCC contact hour(s). This activity is provided for 0.3 contact hours related to pharmacotherapeutic content. Nurses should only claim credit for the actual time spent participating in the activity.

PHYSICIAN ASSISTANTS

University of Nebraska Medical Center has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2 AAPA Category 1 CME credits. Approval is valid until February 23, 2024. PAs should only claim credit commensurate with the extent of their participation.

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 317-871-0011 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High-speed internet connection
• Internet browser (current version) – Firefox, Safari, Chrome, or Explorer
  • Cookies and JavaScript must be enabled in the browser